top of page

Insync's Global Quality Equity Fund earns Zenith's approval

Following on from a five-star rating from Canstar and SQM’s four-star rating, Insync’s Global Quality Equity Fund has just earned an 'Approved' rating from Zenith, as part of their 2022 international sector review.


Insync is one of only two new entrant managers in their 'Core/Neutral' category of international funds. Zenith categorised Insync's wholly integrated ESG approach as 'Aware'.


"Insync is also one of only seven active, broad-focused unlisted global managers added in 2022," said Insync's CIO Monik Kotecha.


“Released in 2018, our Global Quality Equity Fund represents the ‘long-only’ unit class of our longstanding Capital Aware Fund (with its added put protection) established back in 2009,” Mr Kotecha said.


“With the fund meeting its formal performance objective, we are one of a handful of Quality managers in their Core sector; that also possesses a long and proven track record.”


Everyone's talking about it, read it here:











 
Disclaimer
Equity Trustees Limited (“EQT”) (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Insync Global Quality Fund and the Insync Global Capital Aware Fund. EQT is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This information has been prepared by Insync Funds Management Pty Ltd (ABN 29 125 092 677, AFSL 322891) (“Insync”), to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Insync, EQT nor any of its related parties, their employees or directors, provide and warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product.
23 views0 comments
bottom of page